Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$267.07+7.79 (+3.00%)
Close on Nov 12, 2026Market cap $16.55BP/E 21.7Yield –
Ascendis Pharma A/S enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Ascendis Pharma A/S's enterprise value was $16.04B on Nov 11, 2026, against $13.23B a year earlier. Over the last 5 years it ranged from $3.98B to $16.99B, with a median of $8.03B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $16.04B | +20.7% |
| 2025 | Dec 31, 2025 | $13.29B | +63.7% |
| 2024 | Dec 31, 2024 | $8.12B | +12.7% |
| 2023 | Dec 29, 2023 | $7.20B | +5.7% |
| 2022 | Dec 30, 2022 | $6.82B | -0.7% |
| 2021 | Dec 31, 2021 | $6.87B | -13.9% |
| 2020 | Dec 31, 2020 | $7.98B | +35.1% |
| 2019 | Dec 31, 2019 | $5.90B | +159.1% |
| 2018 | Dec 31, 2018 | $2.28B | +168.8% |
| 2017 | Dec 29, 2017 | $847.38M | +138.8% |
| 2016 | Dec 30, 2016 | $354.79M | – |
See a number that looks wrong?